Amidst the evolving landscape of the COVID-19 pandemic, our company has embarked on an essential project named STABVAC4COV. This groundbreaking initiative aims to develop mRNA-based vaccines tailored specifically to combat the highly transmissible Delta variant of SARS-CoV-2.
With the main objective of creating an effective preventive measure against the Delta variant, our dedication to innovation and public health shines brighter than ever. Join us on this critical journey towards a safer, healthier future for all.
STABVAC4COV: DEVELOPMENT OF mRNA-BASED THERMOSTABLE VACCINES AGAINST THE DELTA VARIANT OF SARS-COV-2
Dossier no: EXP-00145740/MIP-20211002
Main objective of the project: development of a vaccine against the Delta variant of SARS-CoV-2 based on messenger RNA (mRNA) technology that is effective in preventing the disease.
Deadline: From 13/09/2021 to 31/12/2023.
Project funded by the European Union – Next Generation EU within the Recovery, Transformation and Resilience Plan. Subsidised by the CDTI.
Grant awarded: 375,856.00 €.
STABVAC4COV: DESARROLLO DE VACUNAS TERMOESTABLES BASADAS EN mRNA FRENTE A LA VARIANTE DELTA DEL SARS-COV-2
Nº expediente: EXP-00145740/MIP-20211002
Objetivo principal del proyecto: desarrollo de una vacuna frente a la variante Delta de SARS-CoV-2 basada en la tecnología de RNA mensajero (mRNA) que resulte eficaz en la prevención de la enfermedad.
Plazo de realización: Desde el 13/09/2021 al 31/12/2023
Proyecto financiado por la Unión Europea – Next Generation EU dentro del Plan de Recuperación, Transformación y Resiliencia. Subvencionado por el CDTI.
Subvención concedida: 375.856,00 €
About 53Biologics:
53Biologics is a CDMO with specialized in biologics production, from pDNA to proteins. In order to serve as leaders in biologics development and manufacturing, our mission is to support you whenever you need us, starting in preclinical development up to commercialization.
For more information contact Patricia De La Madrid, Marketing & Business Development Manager at 53Biologics through this email: pdelamadrid@53biologics.com